Company: PTPI
Filing Date: 2025-02-10
Form Type: S-1/A
Source: 0001410578-25-000108
Chunk: 267

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-10
Form: S-1/A
Chunk 267
---
 Warrants

The following is a summary of warrants for the nine months ended September 30, 2024:

| ​                                                        
 ​                                                        
 ​                                                        
 ​                                                        
 ​                                                        | ​ 
 ​ 
 ​ 
 ​ |                  ​ 
                  ​ 
                  ​ 
                  ​ 
 Number of Warrants | ​ 
 ​ 
 ​ 
 ​ | ​                
 ​                
 ​                
 Weighted-Average 
 Exercise Price   |      ​ 
      ​ 
      ​ | ​ 
 ​ 
 ​ 
 ​ |                ​ 
                ​ 
                ​ 
        Remaining 
 Contractual Term | ​ 
 ​ 
 ​ 
 ​ | ​           
 Aggregate   
 Intrinsic   
 Value ($ in 
 thousands)  | ​ |
|:---------------------------------------------------------|:--|-------------------:|:--|:-----------------|-------:|:--|-----------------:|:--|:------------|:--|
| Warrants outstanding - December 31, 2023                 |   |          8,203,839 | ​ | $                |  14.93 | ​ |              4.3 | ​ | $           | — |
| Warrants issued                                          |   |                  — | ​ | ​                |      — | ​ |                — | ​ | ​           | — |
| Warrants exercised                                       |   |                  — | ​ | ​                |      — | ​ |                — | ​ | ​           | — |
| Warrants expired                                         |   |            -15,097 | ​ | ​                | 252.53 | ​ |                — | ​ | ​           | — |
| Warrants outstanding and exercisable- September 30, 2024 |   |          8,188,742 | ​ | $                |  14.49 | ​ |              3.5 | ​ | $           | — |

12) Dilutive convertible securities

The following table summarizes the potentially dilutive securities convertible into common shares that were excluded from the calculation of diluted net income (loss) per share because their inclusion would have been antidilutive:

| ​                                    | ​ |                          ​ | ​ |          ​ | ​ |                         ​ | ​ |          ​ |
| ​                                    | ​ | For the Three Months Ended |   |            | ​ | For the Nine Months Ended |   |            |
| ​                                    | ​ |              September 30, |   |            | ​ |             September 30, |   |            |
| ​                                    |